Journal of Oncology Pharmacy Practice This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature
We report the first case of ipilimumab-induced progressive necrotic myelopathy. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - April 21, 2016 Category: Cancer & Oncology Authors: Abdallah, A.-O., Herlopian, A., Ravilla, R., Bansal, M., Chandra-Reddy, S., Mahmoud, F., Ong, S., Gokden, M., Hutchins, L. Tags: Case Reports Source Type: research

Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy
Ipilimumab, monoclonal antibody against cytotoxic T-lymphocyte antigen-4 and, radiotherapy are commonly used to treat unresectable and metastatic melanoma. As a result of upregulation of immune system with ipilimumab, many immune-related adverse effects, such as dermatitis, colitis, hepatitis, and hypophysitis, have been previously reported in literature. Typically, these effects are treated with high-dose steroids and mostly heal up. Here, we report a case who was receiving radiotherapy due to metastatic malignant melanoma with atypical generalized rash, which was enlarged with concurrent ipilimumab treatment. (Source: Jo...
Source: Journal of Oncology Pharmacy Practice - April 21, 2016 Category: Cancer & Oncology Authors: Eryılmaz, M. K., Mutlu, H., Salim, D. K., Musri, F. Y., Tural, D., Bassorgun, I., Coskun, H. S. Tags: Case Reports Source Type: research

Itraconazole therapy in a pancreatic adenocarcinoma patient: A case report
Conclusion There would need to be much more research performed to determine if this agent had a role as a chemotherapy agent; however, health care professionals should be aware of itraconazole’s potential antineoplastic mechanisms. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - April 21, 2016 Category: Cancer & Oncology Authors: Lockhart, N. R., Waddell, J. A., Schrock, N. E. Tags: Case Reports Source Type: research

Severe and irreversible myelopathy after concurrent systemic and intrathecal nucleoside analogue treatment for refractory diffuse large B-cell lymphoma: A case report and review of the literature
We report a patient with refractory diffuse large B-cell lymphoma who developed irreversible, severe spinal neurotoxicity after concurrent treatment with intrathecal and systemic cytarabine. Shortly after concomitant administration of intrathecal triple therapy (MTX, dexamethasone and cytarabine) and high-dose systemic cytarabin (R-DHAP protocol) the patient lost control of bowel and bladder function and developed an ascending, irreversible paraplegia. Infectious or neoplastic diseases of the spinal cord were ruled out. A magnetic resonance imaging scan of the spine resulted in a diagnosis of toxic myelitis. Previously obs...
Source: Journal of Oncology Pharmacy Practice - April 21, 2016 Category: Cancer & Oncology Authors: Alsdorf, W. H., Schmitz, M., Schieferdecker, A., Dierlamm, J., Bokemeyer, C., Binder, M. Tags: Case Reports Source Type: research

Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response
Conclusions/Summary Temozolomide is an increasingly described treatment option for refractory pituitary adenomas and carcinomas. In the current report, we document rapid biochemical response following retreatment with temozolomide in aggressive pituitary adenoma. When "off label" salvage therapy with temozolomide is offered for patients with recurrent prolactinomas, retreatment at the time of recurrence can be considered. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - April 21, 2016 Category: Cancer & Oncology Authors: Strowd, R., Salvatori, R., Laterra, J. Tags: Case Reports Source Type: research

Physician-pharmacist collaboration for oral chemotherapy monitoring: Insights from an academic genitourinary oncology practice
Conclusion Our program led to identification of a number of potentially clinically significant issues for patients on oral chemotherapy and demonstrated the benefit of the pharmacist in the multidisciplinary team to assist in addressing them. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - April 21, 2016 Category: Cancer & Oncology Authors: Holle, L. M., Puri, S., Clement, J. M. Tags: Practice Issues Source Type: research

Prophylaxis and treatment recommendations for sinusoidal obstruction syndrome in adult and pediatric patients undergoing hematopoietic stem cell transplant: a review of the literature
Sinusoidal obstruction syndrome, a complication occurring early after hematopoietic stem cell transplantation, is a concern for clinicians. There are no guidelines to direct clinicians on the optimal way to prevent and treat this disease. Newer data show that defibrotide is a promising drug both for prevention and treatment, although it is not yet FDA approved. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - April 21, 2016 Category: Cancer & Oncology Authors: Hopps, S. A., Borders, E. B., Hagemann, T. M. Tags: Review Articles Source Type: research

Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data
In conclusion, there were no clinically relevant interactions between NETU and PALO, or NEPA and oral contraceptives (based on levonorgestrel and ethinylestradiol exposure). Coadministration of NETU or NEPA with CYP3A4 inducers/inhibitors/substrates should be done with caution. Dose reduction is recommended for DEX. Dose adjustments are not needed for NETU coadministration with P-gp substrates. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - April 21, 2016 Category: Cancer & Oncology Authors: Natale, J. J., Spinelli, T., Calcagnile, S., Lanzarotti, C., Rossi, G., Cox, D., Kashef, K. Tags: Review Articles Source Type: research

The role of netupitant and palonosetron in chemotherapy-induced nausea and vomiting
The combination of netupitant and palonosetron was approved by the Food and Drug Administration in October 2014 for the prevention of acute and delayed chemotherapy-induced nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic chemotherapy. Netupitant and palonosetron is available as a single capsule to be administered prior to each cycle of chemotherapy. The approval was based on phase II and III data in patients undergoing treatment with moderately and highly emetogenic chemotherapy. Netupitant and palonosetron’s benefits include a convenient dosage form, dual-targeted m...
Source: Journal of Oncology Pharmacy Practice - April 21, 2016 Category: Cancer & Oncology Authors: Abramovitz, R. B., Gaertner, K. M. Tags: Review Articles Source Type: research

Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics
The presence of activating gene mutations in the epidermal growth factor receptor of non-small cell lung cancer patients is predictive (improved progression-free survival and improved response rate) when treated with small molecule tyrosine kinase inhibitors such as gefitinib, erlotinib and afatinib. The two most common mutations that account for greater than 85% of all EGFR gene mutations are in-frame deletions in exon 19 (LREA deletions) and substitution in exon 21 (L858R). Exon 18 mutations occur much less frequently at about 4% of all EGFR gene mutations. Together, exon 19 deletion and exon 21 L858R gene substitution a...
Source: Journal of Oncology Pharmacy Practice - April 21, 2016 Category: Cancer & Oncology Authors: Chung, C. Tags: Review Articles Source Type: research

Effects of gender on capecitabine toxicity in colorectal cancer
Conclusion Female colorectal cancer patients experience a higher dose-limiting toxicity incidence than male patients when given adjuvant capecitabine dosed according to body surface area. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - April 21, 2016 Category: Cancer & Oncology Authors: Ilich, A. I., Danilak, M., Kim, C. A., Mulder, K. E., Spratlin, J. L., Ghosh, S., Chambers, C. R., Sawyer, M. B. Tags: Original Articles Source Type: research

Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients
Conclusions Higher than usual vancomycin doses may be required to treat serious MRSA infections in pediatric patients. The currently recommended dose of 60 mg/kg/day is unlikely to achieve the targets in most subjects. The optimal vancomycin dosing in pediatric cancer patients requires further investigations. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - April 21, 2016 Category: Cancer & Oncology Authors: Abdel Hadi, O., Al Omar, S., Nazer, L. H., Mubarak, S., Le, J. Tags: Original Articles Source Type: research

Assessment of mental health literacy in patients with breast cancer
Conclusions Our results suggest that the mental health literacy of breast cancer patients was inadequate. Intervention and management strategies could be implemented to teach these patients about evidence-based treatments and professional help that are specific to mental disorders. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - April 21, 2016 Category: Cancer & Oncology Authors: Cheung, Y. T., Ong, Y. Y., Ng, T., Tan, Y. P., Fan, G., Chan, C. W., Molassiotis, A., Chan, A. Tags: Original Articles Source Type: research

Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity
Conclusions Nephrotoxicity is a possible complication of therapy with high-dose methotrexate with most instances comprising grade 1–2 toxicity. Male gender, low albumin, and administration of interacting drugs or furosemide during high-dose methotrexate clearance may predispose patients to nephrotoxicity. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - April 21, 2016 Category: Cancer & Oncology Authors: Wiczer, T., Dotson, E., Tuten, A., Phillips, G., Maddocks, K. Tags: Original Articles Source Type: research

Pegfilgrastim use and bone pain: a cohort study of community-based cancer patients
Conclusions Pegfilgrastim is commonly used for primary prophylaxis during the first cycle of chemotherapy. Hospitalizations for febrile neutropenia occurred most commonly among patients without primary prophylaxis. Pegfilgrastim-associated bone pain occurred in a similar percentage, as reported in randomized controlled trials but less than that reported by survey. Loratadine was the most commonly employed medication to mitigate this adverse effect. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - April 21, 2016 Category: Cancer & Oncology Authors: Pawloski, P. A., Larsen, M., Thoresen, A., Giordana, M. D. Tags: Original Articles Source Type: research